Seeking Alpha

Jerryg

Jerryg
Send Message
View as an RSS Feed
View Jerryg's Comments BY TICKER:
Latest  |  Highest rated
  • All Amarin Eyes On Sunday's Prescription Data [View article]
    Please explain why the FDA would agree to a SPA, set the primary and secondary endpoints, receive documentation that the drug did indeed astoundenly hit both primary and secondary endpoints, accept the SPA application and then refuse to approve it.

    May 24, 2013. 04:06 PM | 2 Likes Like |Link to Comment
  • Italian OTC Fish Oil Study Has No Bearing On Vascepa Outcomes [View instapost]
    For the record, Joe Bruno (JB) handled my call to IR better than anyone I have dealt with over the years. I usually view the IR head as a worthless position seated by a monkey.

    With regards to the call I placed to AMRN back in late March and left a message requesting a call back. I never expected it to happen but JB called back the next day apologizing for not returning my phone call earlier. The guy spent roughly (5) minutes answering my questions in detail and using clarity. The only other time I was impressed as this event was when I called the VRTX IR dept.

    The tone in JB's voice told me that something good was happening at AMRN although it remains to be seen if AMRN can pull this off to the expectations of some people here.
    May 10, 2013. 11:39 AM | 1 Like Like |Link to Comment
  • Amarin Will Be Granted NCE [View instapost]
    I'm not exactly going to hold my breath for this stock to go up anytime soon. It seems to be in firm control of "investors" who wish to see it stay below $7.

    If management so much as gives us the "the next (3) months will be exciting times", shareholders can just kiss it good-bye. If management fails to have their ducks in a row with regards to providing solid guidance for Vascepa sales, the stock price will crater. If they sound like they are at a funeral, then the market will punish the stock.

    Management needs to provide WS with a solid game plan and reasons for pushing the price back above $8. If not, then I have to wonder if management is aiming for another 1-10 reverse split. (heavy sarcasm)
    May 3, 2013. 11:35 PM | 1 Like Like |Link to Comment
  • Amarin Will Be Granted NCE [View instapost]
    Hoping management brings their "A" game to the conference call. Anything less and the stock will most likely see a haircut similar to the one witnessed after the 1st Qtr. CC.
    May 3, 2013. 03:31 PM | Likes Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Thank you for the follow-up. It is appreciated.
    Apr 25, 2013. 03:21 PM | Likes Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Has AMRN provided any kind of estimated date for when the interim results for the Reduce-It trials might be released?
    Apr 25, 2013. 01:19 PM | Likes Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Home_Builder, I understand what you are saying and agree with the logic but it doesn't always happen according to "scripture". On top of that, what cash flow does AMRN have at the given moment? What metrics, as you put it, does AMRN have that will entice a company to plunk down a $25 bid. AMRN has drug that is supposed to sell billions but is having a hard time gaining traction with scripts!

    All a company has to do is wait for AMRN to sink to say, $4.50 or $5 and then offer $12-$15 in a hostile bid and I guarantee you they would have quite a few shares tendered their way. HGSI went to GSK via this same scenario. HGSI actually had Goldman Sachs, I believe it was GS, work up a 'fair value" that came in around $19-$21. So GSK upped their bid to from $13 to $14.25 being the generous Brits that they were.

    Similar to Steve's example mentioned earlier, I bought when the price was less than a $1, sold a bunch in the high 20's/low 30's and then watched the remaining bunch slip back to $7. Lesson learned. What sucked is that it later came out that AMGN had, at one time, offered $35 a share for HGSI and management turned it down.

    Same thing is happening here with AMRN. The price is being pushed down and pushed down and pushed down. You cannot convince me that management did not have a reasonable bid in front of them.

    I hear what you and Steve are saying but the price of AMRN is heading in the opposite direction. This is not a stock that is acting like a buyout candidate anytime soon. Two more months of .10 cent losses each day and the stock will be at zero.
    Apr 25, 2013. 01:06 AM | 1 Like Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Steve, I never said Amarin is asking for more money. What I did mention is that you have never addressed "Amarin's plea to raise the debt limit". As you would say, "you know that".

    I will not convolute your blog with Item 7 from the Proxy statement for the shareholders' meeting, but it specifically requests shareholders to allow for the debt ceiling to be raised. The company is burning through cash like there is no tomorrow. They are launching a drug, funding trials and paying large bonuses to officers.

    At approximately the time when this Proxy was released is when the stock price began to continuously slip. The market does not like it and the shorts are taking full advantage of it. We are currently at a new 52 week low at approx. $6.34!! (Down another 30 cents.)

    Given the current revenue stream (or lack of it), the company needs to figure things out quickly or there will not be much need to figure things out down the road.

    I can appreciate the hard work you have performed trying to educate people on AMRN's "possible" value but maybe it is time to step back and acknowledge that market forces are dictating what happens with this company and that maybe, just maybe, shareholders will be lucky to ever see the $8's or $9's again, let alone $25+. (I just wonder if some news has leaked from the FDA regarding NCE.)

    To me, the need to borrow more funds is not a good sign. Are they planning to launch Anchor on their own? If not, they cannot surely expect to get $20+ a share in a buyout when their stock is at a 52 week low. Something has to give!!

    By the way, thank you for allowing my previous post to go through.
    Apr 24, 2013. 07:26 PM | 1 Like Like |Link to Comment
  • Amarin Set To Go After Expanded TG Market In Q4 2013! [View instapost]
    Interesting you have not discussed Amarin's current plea to raise the debt limit. Has it ever occurred to you that this company does not have the cash to market this drug nor does it have any suitors in the wings to bail it out?
    Apr 24, 2013. 02:39 AM | Likes Like |Link to Comment
  • My 5 Summer Stock Market Flings For 2013 [View article]
    Brian, I have found your articles regarding AMRN to be in direct conflict with the articles of another unnamed SR author who is continuously estimating a $28-32 BO, is claiming a good number of prescriptions are being sold but not captured by the data agencies and is currently stating that prescription sales are going well and that the stock should be approx. $12-15.

    Up to this point in time, your articles and predictions regarding AMRN have been spot on.

    My question is this: is it wise to short the stock with the upcoming catalysts such as a potential for sNDA acceptance, a possible postive NCE decision, the combo data with a statin and a chance for decent prescription data? I assume you have considered the above and am interested in your thesis for shorting AMRN given the above. Are you assuming that none of the above occur?

    In advance, thanks for your response.
    Apr 19, 2013. 06:19 PM | Likes Like |Link to Comment
  • Amarin's 'All-In' On Vascepa Makes It A Massive Risk [View article]
    StephenHandel, kudos to you for exposing SR. He banned/censored me from posting on his blogs/articles because I dared to question him. As far as I am concerned, you have been hitting the nail on the head with regards to exposing him for his inaccuracies and blatant deceptions.

    In addition to daring to question SR, you also have been pretty much right-on with your assessment of AMRN.
    Mar 26, 2013. 06:47 PM | Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    "Anyway, everyone, I am going to be going quiet for a period of time."

    And disappear you have done. Amazing...I predicted this a few short hours ago and I'm on target.


    Dec 11, 2012. 05:25 PM | Likes Like |Link to Comment
  • The Latest On Amarin - How Will The Investment Pay Off? [View article]
    Actually, Yazz is presenting a point of view that you may not adhere to but in actuality may be just as valid as yours, Steve. So far, your points of view, while logically well thought out and presented intelligently, have not really panned out nor is there any guarantee that they will ever come to fruition.

    Yazz is neither offensive nor inappropriate (modern day America no-no's) with his presentations. He appears to subscribe to the same theory that this will be bought out but his thesis is more or less warning readers that current strategies used management could quite possibly be more detrimental to the share price thus pro

    In other words, Yazz is providing the other side to an ongoing debate regarding how management has handled the entire Vascepa affair.

    The fact that you don't want to deal with opinions that differ from yours is quite telling. You want people to buy into your theories and writings but should something think outside your "box" they are subjected to ridicule and scorn.

    I'm not a always a fan of AF but at least he doesn't bully people to either "tow the line" or they will never be able to read his writing again. (No....I am not AF nor Yazz.)

    No doubt you will boot me for talking back to you and defending free speech.
    Dec 11, 2012. 05:24 PM | 2 Likes Like |Link to Comment
  • The Price May Be Increasing For An Amarin Buyout [View article]
    "i just pay attention the the facts and fundementals, and they both look solid to me."

    Is it possible that maybe you are misinterpreting the "facts" and "fundamentals"?

    As far as fundamentals go, Amarin has basically zero equity and will soon have a mountain of debt.

    As far as facts go, Amarin is getting absolutely crushed today. Over 5 million shares traded in the first hour and it is dropping like a rock. Amarin management has not even laid the groundwork for managed care reimbursement and they have wasted over four months doing absolutely nothing!! Oh...let me correct myself.....they HAVE sold their own shares.

    I sure hope you are a better professor and consultant than you are as an analyst. I have no doubt you will disappear as Amarin keeps dropping. You managed to suddenly appear to help "rah rah" Amarin and no doubt you will suddenly disappear way before the rats leave the ship.
    Dec 11, 2012. 10:31 AM | Likes Like |Link to Comment
  • The Latest On Amarin - How Will The Investment Pay Off? [View article]
    For the amount of salary and options begin paid to Joe Z., I believe he should have been better prepared for all of the possible potentials and how to deal with them. Not even having dealt with the managed care and tier pricing begs to ask just what the heck is he doing besides being silent.
    Dec 11, 2012. 01:49 AM | Likes Like |Link to Comment
COMMENTS STATS
15 Comments
4 Likes